---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-003775"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:44:22.241878+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics reports FY2023 net loss $7.7M; Phase 3 LEVEL trial underway

## Summary
- Cash $9.8M at Dec 31, 2023; Feb 2024 public offering netted ~$8.0M.
- Net loss $7.7M (FY2023) vs $11.0M (FY2022); R&D expense down to $3.2M.
- First patient enrolled in Phase 3 LEVEL study for TNX-103 (oral levosimendan) in PH-HFpEF.
- Secured global commercial and IP rights for levosimendan in PH-HFpEF; topline data expected H2 2025.
- KOL event 'LEVEL Setting' scheduled for April 18, 2024.

## SEC filing metadata
- accession: 0001654954-24-003775
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424003775/0001654954-24-003775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424003775/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-003775
- JSON: https://secwatch.observer/filing/0001654954-24-003775.json
- Plain text: https://secwatch.observer/filing/0001654954-24-003775.txt

## Key facts
- Earnings Releases
  TENAX THERAPEUTICS, INC. reported year ended December 31, 2023 results: net income $7.7 million.
  - Period: year ended December 31, 2023
  - Net income: $7.7 million
  - Result: reported results
  source text: Tenax Therapeutics reported a net loss for 2023 of $7.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424003775/0001654954-24-003775-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.